Invo Bioscience, Inc. ( (IVF) ) has released its Q1 earnings. Here is a breakdown of the information Invo Bioscience, Inc. presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
INVO Fertility, Inc. is a healthcare services company focused on the fertility market, offering innovative assisted reproductive technology solutions, including the INVOcell medical device and operating fertility clinics. In its latest earnings report for the quarter ending March 31, 2025, INVO Fertility reported a total revenue of $1.64 million, a slight increase from the previous year. However, the company faced a significant net loss of $17.4 million, primarily due to a $14.6 million impairment loss related to goodwill. The company’s operating expenses rose sharply to $18.7 million, driven by increased selling, general, and administrative expenses, as well as research and development costs. Despite the financial challenges, INVO Fertility secured $8.7 million in net proceeds from a public offering, which was used to redeem preferred stock and repay debt. Looking ahead, the company plans to expand its operations by growing the Wisconsin Fertility Institute and acquiring additional profitable IVF clinics in the U.S., while continuing to seek additional funding to support its growth strategy.